Researchers from the Institute for Basic Science of Korea and collaborating institutions have designed a new class of peptide-based inhibitors targeting a crucial interface within the SARS-CoV-2 replication complex, offering a potential new avenue for antiviral therapy.

The COVID-19 virus may keep mutating, but new findings from Korean researchers at the Institute of Basic Science (IBS) offer a silver lining: human immunity is adapting, too.